Vaxcyte shares surge as pneumococcal vaccine meets main trial goals

Statements (4)

1. ▲ Bullish

   Vaxcyte stock rose after its experimental pneumococcal vaccine proved it is not inferior to marketed shots from Pfizer and Merck

   investors.comOct 5, 2026 13:18 UTCHigh importance
2. ▲ Bullish

   Vaxcyte's pneumococcal vaccine hit the primary endpoints in a Phase 3 clinical trial

   statnews.comOct 5, 2026 13:10 UTC
3. ▲ Bullish

   Vaxcyte's experimental pneumococcal vaccine hit the primary endpoints in a Phase 3 clinical trial

   statnews.comOct 5, 2026 12:19 UTC
4. ▲ Bullish

   Vaxcyte shares surge as pneumococcal vaccine meets main trial goals

   reuters.comOct 5, 2026 10:37 UTC